Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Nov 18, 11:42 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Yesterday


News

Better Buy: Celgene Corporation vs. Merck & Co.

MRK CELG

Better Buy: Celgene Corporation vs. Merck & Co. Keith Speights, The Motley FoolMotley FoolNovember 17, 2018, 10:02 PM GMT. Two drug stocks diverged in a yellow wood. And sorry I could not buy both and be one investor, long I stood. My apologies to Robert Frost for butchering his famous poem "The Road Not Taken." But Celgene Corporation(NASDAQ: CELG) and Merck & Co.(NYSE: MRK) certainly are two drug stocks headed in different directions. Celgene faces generic competition for its best-selling drug beginning in 2022 at the latest. But the biotech expects to launch five new drugs over the next couple of years that arguably could replace all of the revenue generated by Revlimid.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Merck & Co INC Com (MRK) Position Increased by Wealthfront Inc

MRK MRK

The institutional investor held 120,859 shares of the health care company at the end of 2018Q2, valued at $7.34M, up from 55,832 at the end of the previous reported quarter. Wealthfront Inc who had been investing in Merck & Co Inc Com for a number of months, seems to be bullish on the $197.79B market cap company. Wealthfront Inc, which manages about $1.70 billion and $9.64 billion US Long portfolio, decreased its stake in Vanguard Index Fds Extend Mkt Etf (VXF) by 28,755 shares to 2.45 million shares, valued at $288.91 million in 2018Q2, according to the filing. More news for Merck & Co., Inc. (NYSE:MRK) were recently published by: Streetinsider.com, which released: “Merck (MRK) Begins Rolling Submission of Licensure Application for V920 to FDA” on November 13, 2018.

Read Full Details

Topics:
  • Business
  • Financial
News

Warburg Research Reiterates €103.00 Price Target for Merck KGaA (MRK) – Fairfield Current

JPM MRK

Goldman Sachs Group set a €92.00 ($106.98) price target on Merck KGaA and gave the company a neutral rating in a report on Monday, September 24th. Nord/LB set a €82.00 ($95.35) price target on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 9th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of €98.00 ($113.95). Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, November 16


News

Merck KGaA (MRK) Given a €100.00 Price Target by Oddo Bhf Analysts – Marea Informative

MRK CBK

Merck KGaA (FRA:MRK) received a €100.00 ($116.28) target price from stock analysts at Oddo Bhf in a research report issued to clients and investors on Wednesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Goldman Sachs Group set a €92.00 ($106.98) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, September 12th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have assigned a buy rating to the stock.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

PFE MRK

Immunicum will be responsible for conducting the study and continues to retain all commercial rights to ilixadencel. "We look forward to working with Immunicum to assess ilixadencel with avelumab. As part of our clinical development program for avelumab, this collaboration can help advance our understanding of the potential of immunotherapy combination regimens," said Chris Boshoff, M.D., Ph.D., Senior Vice President and Head of Immuno-oncology, Early Development and Translational Oncology, Pfizer Global Product Development. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.1-3 Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.3-5 In November 2014, Merck KGaA, Darmstadt, Germany, and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab. Indications in the US**The US Food and Drug Administration (FDA) granted accelerated approval for avelumab (BAVENCIO®) for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

Merck KGaA (MRK) PT Set at €103.00 by Warburg Research – PressOracle

MRK

The brokerage currently has a “neutral” rating on the healthcare company’s stock. Credit Suisse Group set a €93.00 ($108.14) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Tuesday, October 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have assigned a buy rating to the stock. Merck KGaA currently has a consensus rating of “Hold” and an average target price of €98.00 ($113.95).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, November 15


News

Chromatography Resin - Global Markets to 2025 featuring Merck, Bio-Rad Labs, Thermo Fisher Scientific, GE Healthcare, Purolite Corp, and many more

MRK

Growing number of Contract Research Organizations (CRO) and Contract Manufacturing Organizations (CMO) and use of chromatography in food quality and safety testing is propelling the market. Synthetic resin will witness the fastest growth in terms of revenue at a CAGR of 7.2% over the forecast period, owing to its high productivity. Asia Pacific is anticipated to witness substantial development and was valued at USD 608.9 million in 2016 owing to rising disposable income and pharmaceutical companies. Chapter 3 Market Variables, Trends, and Scope3.1 Market segmentation3.2 Penetration & growth prospect mapping, 2014 - 20253.3 Value chain analysis3.4 Regulatory framework3.5 Technology overview3.6 Market dynamics3.6.1 Market driver analysis3.6.1.1 High demand considering advances in drug development3.6.1.2 Increasing use of chromatography as a separation technique in food & beverage industry3.6.2 Market restraint analysis3.6.2.1 Costlier than other separation techniques3.7 Key opportunities prioritized3.7.1 New market avenues3.8 Industry analysis - Porter's3.9 PESTEL analysis. Chapter 7 Chromatography Resin Market: Regional Estimates & Trend Analysis7.1 Regional Market Introduction, 2016 & 20257.2 Global Chromatography Resin demand by region, 2014 - 2025 (Thousand liters)7.3 North America7.4 Europe7.5 Asia Pacific7.6 Central & South America (CSA)7.7 Middle East & Africa (MEA).

Read Full Details

Topics:
  • Business
  • Health
  • Science
News

Merck's Keytruda Improves Survival in Esophageal Cancer Study

MRK

It is the seventh most commonly diagnosed cancer and is estimated to be diagnosed in more than 17,000 adults in the United States this year. However, statistical significance for OS was not reached in two patient groups — patients with squamous cell histology and in the entire intention-to-treat (ITT) study population — in the study. The study (KEYNOTE-181) was conducted in patients with advanced esophageal or esophagogastric junction carcinoma whose tumors express PD-L1 with a Combined Positive Score or CPS of 10 or greater. While OS was the primary endpoint of the study, secondary endpoints of the study were progression-free survival (PFS) and objective response rate (ORR), which were not formally tested. Additionally, earlier this week, Merck announced FDA approval of Keytruda for the treatment of advanced hepatocellular carcinoma (HCC), the most common type of liver cancer in patients, previously treated with Bayer/Amgen’s AMGN Nexavar (sorafenib). A key FDA approval last month was the label expansion of Keytruda as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC) – a difficult-to-treat lung cancer patient population - based on data from the phase 3 KEYNOTE-407 study.

Read Full Details

Topics:
  • Business
  • Health
News

NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration Nasdaq:NLNK

MRK

In 2014 the Company entered into a license agreement with Merck to develop, manufacture and commercialize NewLink Genetics’ Ebola vaccine candidate. AMES, Iowa, Nov. 15, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated). This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016 and is anticipated to be completed in 2019. The FDA’s approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Wednesday, November 14


News

Merck (MRK) Stock Moves -0.7%: What You Should Know

MRK

Merck (MRK) closed the most recent trading day at $74.09, moving -0.7% from the previous trading session. Heading into today, shares of the pharmaceutical company had gained 4.76% over the past month, outpacing the Medical sector's loss of 0.16% and the S&P 500's loss of 1.41% in that time. MRK will be looking to display strength as it nears its next earnings release, which is expected to be February 1, 2019. Meanwhile, our latest consensus estimate is calling for revenue of $11.05 billion, up 5.91% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $4.34 per share and revenue of $42.29 billion, which would represent changes of +9.05% and +5.41%, respectively, from the prior year.

Read Full Details

Topics:
  • Business
  • Financial